Title Issue Date
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC Kim, Hye Ryun; Awad, Mark M.; Navarro, Alejandro; Gottfried, Maya; Peters, Solange, et al Issued date: 2023 DOI: 10.1016/j.jtocrr.2023.100572 Source: JTO Clinical and Research Reports[EISSN 2666-3643],v. 4 (11), (Noviembre 2023) SJR: 1,321 - Q1 Artículo
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC Garassino, Marina C.; Gadgeel, Shirish; Novello, Silvia; Halmos, Balazs; Felip, Enriqueta, et al Issued date: 2023 DOI: 10.1016/j.jtocrr.2022.100431 Source: Jto Clinical And Research Reports [2666-3643],v. 4 (1), (Enero 2023) SJR: 1,321 - Q1 Artículo
Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431] (JTO Clinical and Research Reports (2023) 4(1), (S2666364322001552), (10.1016/j.jtocrr.2022.100431)) Garassino, Marina C.; Gadgeel, Shirish; Novello, Silvia; Halmos, Balazs; Felip, Enriqueta, et al Issued date: 2025 DOI: 10.1016/j.jtocrr.2025.100892 Source: JTO Clinical and Research Reports[EISSN 2666-3643],v. 6 (10), (Octubre 2025) SJR: 1,321 - Q1 Artículo